# Tianran LIU

> Tianran LIU is a Series B investor at Vertex Ventures China backing Health Care and Biotechnology. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Vertex Ventures China](https://shizune.co/investors/profile/vertex-ventures-china)
- Total investments: 10
- Last investment: Oct 2025
- Lead investor: 40%
- Last updated: Aug 2026

Tianran LIU is a partner at Vertex Ventures China. She completed her education at Amsterdam Business School.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 60% |
| Biotechnology | 4 | 40% |
| Medical | 3 | 30% |
| Biopharma | 2 | 20% |
| Pharmaceutical | 2 | 20% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 6 | 60% |
| Series A | 2 | 20% |
| Seed | 1 | 10% |
| Series C | 1 | 10% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 8 | 80% |
| United States | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Yike Medical | Yike Medical specializes in non-invasive neuromodulation technology, focusing on the research, development, and application of advanced medical devices that improve neurological function and patient outcomes. |  | Seed | Oct 13, 2025 |  |
| Edge Medical Robotics | Edge Medical Robotics, Inc. was founded in Longgang, Shenzhen, China on May 4, 2017. It is committed to researching and promoting most advanced smart equipment in the world，polishing the ultimate product with the spirit of pursuing excellence and fineness, improving surgical safety and treatment efficacy, and contributing to uprising the level ofsocial health. | $200M | Series C | Nov 05, 2021 |  |
| Pinnacles Medical | Pinnacles Medical is an AI based developing and researching firm that evaluate needs and integrates diagnosis to provide overall solutions. | $46.9M | Series A | Oct 21, 2021 |  |
| Regor Therapeutics | Regor Therapeutics is a clinical-stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary CARD (Computer Accelerated Rational Discovery) Platform, seamlessly integrating structural biology, computational chemistry, therapeutic biology, medicinal chemistry, andclinical development. Regor has assembled a world-class scientific team and demonstrated high efficiency in producing best- and first-in-class molecules. | $90M | Series B | Feb 18, 2021 |  |
| Edge Medical Robotics | Edge Medical Robotics, Inc. was founded in Longgang, Shenzhen, China on May 4, 2017. It is committed to researching and promoting most advanced smart equipment in the world，polishing the ultimate product with the spirit of pursuing excellence and fineness, improving surgical safety and treatment efficacy, and contributing to uprising the level ofsocial health. | $92.8M | Series B | Jan 26, 2021 |  |
| RecBio | Focusing on major innovative vaccines with independent intellectual property rights. | $226M | Series B | Nov 11, 2020 |  |
| ImageneBio | It is a leading biotech company focused on immunology-related therapeutic areas. | $21M | Series B | Nov 08, 2020 |  |
| Harbour Biomed | Harbour BioMed is a developer of bio-therapeutics aimed at immuno-oncology and inflammatory diseases. The company engages in discovery and development programs that are centered around two patented transgenic mouse platforms for generating both fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb) based immune cell engager(HBICETM) bispecific antibodies, thereby enabling medical professionals to generate potential therapeutic antibodies and accelerate drug discovery and development. | $85M | Series B | Aug 27, 2018 |  |
| AnHeart Therapeutics | AnHeart Therapeutics is a developer of innovative pharmaceutical products. The company is focused on acquiring, developing and commercializing innovative pharmaceutical products that improve human health and quality of life. It's main research product, AB-106, is an oral, highly selective ROS1/NTRK small molecule inhibitor. |  | Series A |  |  |
| Haici Technology | Haiui Health Technology is a mobile platform for hospitals to connect patients, optimise hospital visits and streamline admin workflow. |  | Series B |  |  |

10 of 10 investments shown.

## Co-investors
- [LYFE Capital](https://shizune.co/investors/profile/lyfe-capital-2) — VC Fund, 3 deals together
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund, 2 deals together
- [3H Health Investment](https://shizune.co/investors/profile/3h-health-investment) — VC Fund, 1 deal together
- [Advantech Capital](https://shizune.co/investors/profile/advantech-capital) — VC Fund, 1 deal together
- [BioVenture](https://shizune.co/investors/profile/bioventure) — VC Fund, 1 deal together
- [Boyu Capital](https://shizune.co/investors/profile/boyu-capital) — VC Fund, 1 deal together

## About Vertex Ventures China

VC Fund · Beijing, China

Vertex Ventures China invests in high-growth internet and technology start-ups across mainland China, and provides funding support and value-add services to portfolio companies in their growth stage. Based in Beijing and Shanghai, Vertex Ventures China collaborates with the Vertex network of ventures funds across US, Israel, Southeast Asia, andIndia, and under auspices of Vertex Holdings providing local knowledge with global perspective.

5 contacts available at Vertex Ventures China.

| Name | Title | Profile |
| --- | --- | --- |
| Choon Chong TAY | Managing Partner | https://shizune.co/investors/profile/tay-choon-chong |
| Jianwei YUAN | Partner | https://shizune.co/investors/profile/jianwei-yuan |
| Li Wei | Managing Partner | https://shizune.co/investors/profile/li-wei-7b08 |
| Ren Gang | Executive Director | https://shizune.co/investors/profile/ren-gang |
| Tianran LIU | Partner | https://shizune.co/investors/profile/tianran-liu-2da1 |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Tianran LIU invest in?

Tianran LIU invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series A stage. Most of the 10 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Tianran LIU last invest?

The most recent investment recorded for Tianran LIU closed in Oct 2025. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co